John M. Burke, MD, on Newly Diagnosed DLBCL: frontMIND Trial

May 31, 2026 By The ASCO Post Staff

John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).

Related Content